Pharma Journalist -

BiomX Inc. a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, announced that it has entered into a collaboration with…
Read More...

Selexis SA and Igyxos announced that they have entered into a service agreement to develop Igyxos’ first-in-class monoclonal antibody (mAb) drug candidate for the treatment of human…
Read More...

Oxford Biomedica plc announced that it has signed an 18 month supply agreement under a three year Master Supply and Development Agreement with AstraZeneca UK Ltd for large-scale…
Read More...

Gilead Sciences, Inc. announced an agreement with Jounce Therapeutics, Inc. a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and…
Read More...

reVision Therapeutics, Inc. a privately-held, early stage biopharmaceutical company focused on the development and commercialization of innovative therapies for ocular and rare…
Read More...

Vir Biotechnology, Inc. and GlaxoSmithKline plc announced that the first patient was dosed last week in a phase 2/3 study with VIR-7831 (also known as GSK4182136), a fully human…
Read More...

Ionis Pharmaceuticals, Inc. and its affiliate Akcea Therapeutics, Inc. announced that they have entered into a definitive agreement under which Ionis will acquire all of the outstanding…
Read More...

SOTIO, a clinical stage immuno-oncology company owned by PPF Group, announced that it has acquired the rights to Unum Therapeutics’ (Nasdaq: UMRX) BOXR cell therapy platform and BOXR…
Read More...

Applied BioMath, the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, announced a…
Read More...

Nestlé and Aimmune Therapeutics, Inc. a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies (Aimmune), have entered into…
Read More...